Gapping down
In reaction to earnings/guidance:
- JRVR -23.9% (also announced $175 mln stock offering), FSLY -18.4% (also CFO to step down), RKT -12.9%, YELL -12.8%, ETSY -11.1%, VAPO -9.8%, AVNW -9.5%, TXG -8.7%, CAH -8.2%, CENX -7.1%, TWO -6.5%, RDFN -6.1%, IIVI -5.9%, MTW -5.4%, MRNA -5.4%, CTSH -4.9%, INSG -4.9%, TWLO -4.9%, GKOS -4.8%, FATE -4.8%, PWR -4.5%, CCMP -4.2%, USCR -4.2%, UBER -3.9%, NCLH -3.9%, LOPE -3.7%, SRPT -3.3%, APTV -3.3%, ACIW -3.1%, W -2.9%, LAUR -2.9%, KW -2.8%, ALE -2.4%, GOGO -2.4%, FMC -2.3%, EVRG -2.3%, MIDD -2.3%, MTG -2.2%, GDOT -2.2%, GBT -2.1%, WD -2%, KL -2%, TPR -2%, XEC -1.9%, CXW -1.6%, PENN -1.6%, AVYA -1.6%, DCP -1.5%, KRO -1.5%, ING -1.3%, HWM -1.3%, ALB -1.2%, CF -1.2%, EQT -1.1%, MET -1.1%, BE -1.1%, FLT -1%
Other news:
- NVAX -7.1% (announces publication of results for Phase 2b trial conducted in South Africa of NVX-CoV2373)
- ALGT -6.4% (prices offering of 1.35 mln shares of common stock at $219.00 per share)
- MRK -1.1% (FDA approves KEYTRUDA for HER2-positive gastric or gastroesophageal junction adenocarcinoma)
- BE -1.1% (BKR and BE to collaborate on efficient power and hydrogen solutions)
- AMT -1% (prices offering of 9 mln shares of common stock at $244.75 per share)
Analyst comments:
- FMC -2.3% (downgraded to Neutral from Buy at Citigroup)
- PTON -2.3% (downgraded to Neutral from Buy at BofA Securities)
- PFE -1.9% (downgraded to Neutral from Buy at Mizuho)
- OCFC -1.4% (downgraded to Equal-Weight from Overweight at Stephens)